ReviewJournal for immunotherapy of cancer2024

Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018-2022.

Colm Mac Eochagain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.